Total Solutions Provider for the Biopharmaceutical Industry

As a leading partner of the biopharmaceutical industry, Sartorius Stedim Biotech helps its customers to develop their production processes and manufacture biotech medications and vaccines more efficiently. Sartorius Stedim Biotech is a globally operating company with subsidiaries in more than 25 countries and around 11,900 employees worldwide.

The parent company of the Sartorius Stedim Biotech Group is Sartorius Stedim Biotech S.A., headquartered in Aubagne, France and listed on the Euronext stock exchange in Paris. Approximately 74% of the share capital and around 85% of the voting rights of Sartorius Stedim Biotech S.A. are held by Sartorius AG.


Investor Relations

Explore More

Technologies for the Entire Added-Value Chain in Biopharmaceutical Production

Sartorius Stedim Biotech offers a broad portfolio of products that focuses on all major steps in the manufacture of a biopharmaceutical, as well as in process development as prerequisite procedures. Our technologies cover, inter alia, cell line technologies, cell culture media, bioreactors, and a wide range of products for separation, purification, and concentration of biological intermediates and finished products, as well as solutions for their storage and transportation.

Headquartered in Aubagne, France

Related Content

History of Sartorius Stedim Biotech

Follow the development of French biotech company Stedim founded in 1978 up to the merger with Sartorius AG in 2007.

Learn More

Capacity Expansion: Augbagne, France

Check out the latest developments of one of Sartorius' largest locations worlwide and its French headquarters in Aubagne, France.

Learn More


Company Presentation Sartorius Stedim Biotech

PDF 1.9 MB

Insight | Sartorius in Profile

PDF 8.8 MB

Universal Registration Document 2022

PDF 8.4 MB

Contact Us

Get in Touch

Explore Sartorius


Investor Relations

Explore More